Psoriasis Clinical Trial
Official title:
A Survey on the Role and Benefits of Online Social Networks on Filipino Patients With Psoriasis
Verified date | November 2011 |
Source | University of the Philippines |
Contact | n/a |
Is FDA regulated | No |
Health authority | Philippines: Ethics Committee |
Study type | Observational |
With the rise of usage of the internet, online social networks have recently been gaining popularity. Joining these groups can be beneficial to patients with chronic medical illness, such as psoriasis.This was a cross-sectional online survey of psoriasis patients in the Philippines who are members of online support groups. The survey was conducted for a period of three months.The purpose of the research project was to describe the demographics, disease characteristics, activities and benefits of online support groups to Filipino patients with psoriasis. The extent to which members experience empowering processes and outcomes was also evaluated.
Status | Completed |
Enrollment | 124 |
Est. completion date | August 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - diagnosis of psoriasis - individuals who are willing to complete the online survey - proficiency in English - membership in an online psoriasis support network Exclusion Criteria: - nonmembers - unwilling to participate in the study |
Observational Model: Ecologic or Community, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of the Philippines | Philippine Dermatological Society |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Demographic profile of online support users | The sociodemographic profile of the respondents such as age (mean, range), sex, civil status, level of formal education, employment status were described. | 3 months | No |
Primary | Disease characteristics of online support users | The overall health status (poor, average, good), psoriasis severity (mild, moderate, severe), duration of illness of online support groups were evaluated. | 3 months | No |
Secondary | Activities performed and extent of participation of online support users | Participants were also asked regarding their attitudes and experiences with online communities, length of use, log-on frequency and nature of online activities. | 3 months | No |
Secondary | Empowering processes and outcomes experienced by online support group members | The frequency with which empowering processes (exchange information, find recognition, share experiences, encounter emotional support, help others) occurred were measured on a 3-point scale (1-seldom to never, 2-sometimes, 3-often). The outcomes experienced (are better informed, feel more confident in relationship with physician, have improved acceptance, feel more confident with treatment, have enhanced social well-being, have increased optimism and control over the future, have enhanced self-esteem) were assessed on a 3-point scale (1-disagree, 2-neither agree nor disagree, 3-agree). | 3 months | No |
Secondary | Correlation of variables | Intervariable correlation (overall health status/psoriasis severity with frequency/duration of usage, educational level/employment status with frequency of usage) were also be assessed for significance. | 3 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03236870 -
A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
|
||
Completed |
NCT00078819 -
Etanercept (Enbrel®) in Psoriasis - Pediatrics
|
Phase 3 | |
Completed |
NCT04841187 -
Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
|
||
Active, not recruiting |
NCT03927352 -
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT03284879 -
Post-Marketing Surveillance Study of OTEZLA
|
||
Recruiting |
NCT06027034 -
Effectiveness of a Digital Health Application for Psoriasis
|
N/A | |
Not yet recruiting |
NCT06050330 -
CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
|
N/A | |
Recruiting |
NCT05744466 -
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
|
||
Completed |
NCT04149587 -
A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
|
||
Completed |
NCT01384630 -
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
|
Phase 2 | |
Completed |
NCT03998683 -
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
|
Phase 3 | |
Terminated |
NCT03556202 -
A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3)
|
Phase 3 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06077331 -
A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT04316585 -
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
|
Phase 1 | |
Completed |
NCT04894890 -
A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
|
||
Completed |
NCT00358384 -
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
|
Phase 1 | |
Completed |
NCT03757013 -
A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
|
||
Completed |
NCT03265613 -
Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis
|
Phase 1/Phase 2 | |
Completed |
NCT05003531 -
A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis
|
Phase 2 |